Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027

  • Report ID:MRHC - 104274
  • Pages: 180
  • Jun 2020
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours

1. Introduction  
    1.1. Market Definition 
    1.2. Market Ecosystem 
    1.3. Currency 
    1.4. Key Stakeholders 

2. Research Methodology  
    2.1. Research Process
    2.2. Data Collection & Validation
           2.2.1. Secondary Research
           2.2.2. Primary Research
    2.3. Market Assessment
           2.3.1. Market Size Estimation
                     2.3.1.1. Bottom-Up Approach
                     2.3.1.2. Top-Down Approach
                     2.3.1.3. Growth Forecast
           2.3.2. Market Share Analysis
    2.4. Assumptions for the Study
    2.5. Limitations for the Study   

3. Executive Summary  
 

4. Market Insights
    4.1. Market Overview
    4.2. Drivers
           4.2.1. Increasing Global Prevalence of Infectious Diseases
           4.2.2. Growing Awareness for Early Detection Using Specific Diagnostic Tests
           4.2.3. Impact of COVID-19 pandemic 
           4.2.4. Growth in Funding for Research on Infectious Disease Diagnostics 
           4.2.5. Shift in Focus from Centralized Laboratories to Decentralized Point-Of-Care Testing
    4.3. Restraints
           4.3.1. Unfavorable and Inadequate Reimbursement Scenario
    4.4. Opportunities
           4.4.1. Advances in Genomics and Proteomics
           4.4.2. Growing Awareness About Personalized Medicines
           4.4.3. Growth Opportunities in Emerging Economies

5. Global Infectious Disease Diagnostics Market, by Product and Services
    5.1. Introduction
    5.2. Consumables
    5.3. Instruments
    5.4. Software and Services

6. Global Infectious Disease Diagnostics Market, by Technology
    6.1. Introduction
    6.2. Immunodiagnostics
    6.3. Clinical Microbiology
    6.4. Polymerase Chain Reaction (PCR)
    6.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
    6.6. DNA Sequencing & Next-Generation Sequencing (NGS)
    6.7. DNA Microarray
    6.8. Other Technologies

7. Global Infectious Disease Diagnostics Market, by Disease Type
    7.1. Introduction
    7.2. Hepatitis
    7.3. HIV
    7.4. Hospital-Acquired Infections (HAIS)
    7.5. Human Papillomavirus (HPV)
    7.6. Tuberculosis (TB)
    7.7. Influenza
    7.8. Other Infectious Diseases

8. Global Infectious Disease Diagnostics Market, by End User
    8.1. Introduction
    8.2. Hospital/Clinical Laboratories
    8.3. Reference Laboratories
    8.4. Academics/Research Institutes
    8.5. Other End Users    

9. Infectious Disease Diagnostics Market, by Geography
    9.1. Introduction
    9.2. North America
           9.2.1. U.S.
           9.2.2. Canada
    9.3. Europe
           9.3.1. Germany
           9.3.2. U.K.
           9.3.3. France
           9.3.4.  Italy
           9.3.5.  Spain
           9.3.6. Rest of Europe (ROE)
    9.4. Asia Pacific
           9.4.1. China
           9.4.2. Japan
           9.4.3.  India
           9.4.4. Rest of Asia Pacific (ROAPAC)
    9.5. Latin America
    9.6. Middle East and Africa

10. Competitive Landscape

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
      11.1. Abbott Laboratories
      11.2. Danaher Corporation
      11.3. Bio-Rad Laboratories, Inc.
      11.4. biomérieux S.A.
      11.5. F. Hoffmann-La Roche Ltd
      11.6. Bd (Becton, Dickinson And Company)
      11.7. DiaSorin S.p.A.
      11.8. Meridian Bioscience, Inc.
      11.9. Quidel Corporation
      11.10. Thermo Fisher Scientific Inc.

12. Appendix
      12.1. Questionnaire
      12.2. Available Customization

List of Tables

Table 1 Global Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 2 Global Infectious Disease Diagnosis Consumables Market Size, by Country/Region, 2018–2027 ($Million)
Table 3 Global Infectious Disease Diagnosis Instruments Market Size, Country/Region, 2018–2027 ($Million)
Table 4 Global Infectious Disease Diagnostics Software & Services Market Size, Country/Region, 2018–2027 ($Million)
Table 5 Global Infectious Disease Diagnostics Market Size, by Technology, 2018–2027 ($Million)
Table 6 Global Clinical Microbiology Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 7 Global PCR Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 8 Global INAAT Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 9 Global DNA Sequencing & Next-Generation Sequencing Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 10 Global DNA Microarray Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 11 Global Other Technologies Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 12 Global Infectious Disease Diagnostics Market Size, by Disease Type 2018–2027 ($Million)
Table 13 Global Infectious Disease Diagnostics Market Size for Hepatitis, by Country/Region, 2018–2027 ($Million)
Table 14 Global Infectious Disease Diagnostics Market Size for HIV, by Country/Region, 2018–2027 ($Million)
Table 15 Global Infectious Disease Diagnostics Market Size for Hospital-Acquired Infections, by Country/Region, 2018–2027 ($Million)
Table 16 Global Infectious Disease Diagnostics Market Size for Human Papillomavirus, by Country/Region, 2018–2027 ($Million)
Table 17 Global Infectious Disease Diagnostics Market Size for Tuberculosis, by Country/Region, 2018–2027 ($Million)
Table 18 Global Infectious Disease Diagnostics Market Size for Influenza, by Country/Region, 2018–2027 ($Million)
Table 19 Global Infectious Disease Diagnostics Market Size for Other Diseases, by Country/Region, 2018–2027 ($Million)
Table 20 Global Infectious Disease Diagnostics Market Size, by End User, 2018–2027 ($Million)
Table 21 Global Infectious Disease Diagnostics Market Size for Hospital/Clinical Laboratories, by Country/Region, 2018–2027 ($Million)
Table 22 Global Infectious Disease Diagnostics Market Size for Reference Laboratories, by Country/Region, 2018–2027 ($Million)
Table 23 Global Infectious Disease Diagnostics Market Size for Academics/Research Institutes, by Country/Region, 2018–2027 ($Million)
Table 24 Global Infectious Disease Diagnostics Market Size for Other End User, by Country/Region, 2018–2027 ($Million)
Table 25 Global Infectious Disease Diagnostics Market Size, by Country/Region, 2018–2027 ($Million)
Table 26 North America: Infectious Disease Diagnostics Market Size, by Country, 2018–2027 ($Million)
Table 27 North America: Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 28 North America: Market Size, by Technology, 2018–2027 ($Million)
Table 29 North America: Market Size, by Disease Type 2018–2027 ($Million)
Table 30 North America: Market Size, by End User, 2018–2027 ($Million)
Table 31 U.S.: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 32 U.S.: Market Size, by Technology, 2018–2027 ($Million)
Table 33 U.S.: Market Size, by Disease Type 2018–2027 ($Million)
Table 34 U.S.: Market Size, by End User, 2018–2027 ($Million)
Table 35 Canada: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 36 Canada: Market Size, by Technology, 2018–2027 ($Million)
Table 37 Canada: Market Size, by Disease Type 2018–2027 ($Million)
Table 38 Canada: Market Size, by End User, 2018–2027 ($Million)
Table 39 Europe: Market Size, by Country, 2018–2027 ($Million)
Table 40 Europe: Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 41 Europe: Market Size, by Technology, 2018–2027 ($Million)
Table 42 Europe: Market Size, by Disease Type 2018–2027 ($Million)
Table 43 Europe: Market Size, by End User, 2018–2027 ($Million)
Table 44 Germany: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 45 Germany: Market Size, by Technology, 2018–2027 ($Million)
Table 46 Germany: Market Size, by Disease Type 2018–2027 ($Million)
Table 47 Germany: Market Size, by End User, 2018–2027 ($Million)
Table 48 U.K.: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 49 U.K.: Market Size, by Technology, 2018–2027 ($Million)
Table 50 U.K.: Market Size, by Disease Type 2018–2027 ($Million)
Table 51 U.K.: Market Size, by End User, 2018–2027 ($Million)
Table 52 France: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 53 France: Market Size, by Technology, 2018–2027 ($Million)
Table 54 France: Market Size, by Disease Type 2018–2027 ($Million)
Table 55 France: Market Size, by End User, 2018–2027 ($Million)
Table 56 Italy: Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 57 Italy: Market Size, by Technology, 2018–2027 ($Million)
Table 58 Italy: Market Size, by Disease Type 2018–2027 ($Million)
Table 59 Italy: Market Size, by End User, 2018–2027 ($Million)
Table 60 Spain: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 61 Spain: Market Size, by Technology, 2018–2027 ($Million)
Table 62 Spain: Market Size, by Disease Type 2018–2027 ($Million)
Table 63 Spain: Market Size, by End User, 2018–2027 ($Million)
Table 64 ROE: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 65 ROE: Market Size, by Technology, 2018–2027 ($Million)
Table 66 ROE: Market Size, by Disease Type 2018–2027 ($Million)
Table 67 ROE: Market Size, by End User, 2018–2027 ($Million)
Table 68 Asia-Pacific: Infectious Disease Diagnostics Market Size, by Country, 2018–2027 ($Million)
Table 69 Asia-Pacific: Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 70 Asia-Pacific: Market Size, by Technology, 2018–2027 ($Million)
Table 71 Asia-Pacific: Market Size, by Disease Type 2018–2027 ($Million)
Table 72 Asia-Pacific: Market Size, by End User, 2018–2027 ($Million)
Table 73 Japan: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 74 Japan: Market Size, by Technology, 2018–2027 ($Million)
Table 75 Japan: Market Size, by Disease Type 2018–2027 ($Million)
Table 76 Japan: Market Size, by End User, 2018–2027 ($Million)
Table 77 China: Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 78 China: Market Size, by Technology, 2018–2027 ($Million)
Table 79 China: Market Size, by Disease Type 2018–2027 ($Million)
Table 80 China: Market Size, by End User, 2018–2027 ($Million)
Table 81 India: Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 82 India: Market Size, by Technology, 2018–2027 ($Million)
Table 83 India: Market Size, by Disease Type 2018–2027 ($Million)
Table 84 India: Market Size, by End User, 2018–2027 ($Million)
Table 85 ROAPAC: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 86 ROAPAC: Market Size, by Technology, 2018–2027 ($Million)
Table 87 ROAPAC: Market Size, by Disease Type 2018–2027 ($Million)
Table 88 ROAPAC: Market Size, by End User, 2018–2027 ($Million)
Table 89 Latin America: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 90 Latin America: Market Size, by Technology, 2018–2027 ($Million)
Table 91 Latin America: Market Size, by Disease Type 2018–2027 ($Million)
Table 92 Latin America: Market Size, by End User, 2018–2027 ($Million)
Table 93 Middle East & Africa: Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Table 94 Middle East & Africa: Market Size, by Technology, 2018–2027 ($Million)
Table 95 Middle East & Africa: Market Size, by Disease Type 2018–2027 ($Million)
Table 96 Middle East & Africa: Market Size, by End User, 2018–2027 ($Million)
Table 97 Recent Developments, by Company, 2017-2020 

List of Figures

Figure 1 Key Stakeholders
Figure 2 Research Process 
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Infectious Disease Diagnostics Market Size, by Product and Solutions, 2020 VS 2027($Million)
Figure 9 Global Infectious Disease Diagnostics Market Size, by Technology, 2020 VS 2027($Million)
Figure 10 Global Infectious Disease Diagnostics Market Size, by Disease Type 2020 VS 2027($Million)
Figure 11 Hospitals/Clinical Laboratories Expected to Dominate the Global Market, by End User (2019-2027)
Figure 12 Infectious Disease Diagnostics Market, by Region
Figure 13 Market Dynamics
Figure 14 Global Infectious Disease Diagnostics Market Size, by Product and Solutions, 2018–2027 ($Million)
Figure 15 Global Infectious Disease Diagnostics Market Size, by Technology, 2018–2027 ($Million)
Figure 16 Global Infectious Disease Diagnostics Market Size, by Disease Type 2018–2027 ($Million)
Figure 17 Global Infectious Disease Diagnostics Market Size, by End User, 2018–2027 ($Million)
Figure 18 North America: Market Size, by Country, 2018–2027 ($Million)
Figure 19 Europe: Market Size, by Country, 2018–2027 ($Million)
Figure 20 Asia-Pacific: Market Size, by Country, 2018–2027 ($Million)
Figure 21 Key growth Strategies Adopted by Leading Players, 2017-2020
Figure 22 Infectious Disease Diagnosis: Competitive Benchmarking
Figure 23 Market Share Analysis: Infectious Disease Diagnosis Industry, 2018

COVID-19

This report provides pre & post COVID-19 market estimates

Download sample here

The infectious disease diagnostics market is expected to grow at a CAGR of 7.4% from 2020 to 2027 to reach at $23.17 billion by 2027. The epidemiological burden of infectious diseases like severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Ebola, chikungunya, avian flu, swine flu, and Zika has opened door for their early diagnosis & prevention. Similarly, current outbreak of COVID-19 pandemic has tremendously increased the demand for various POC diagnostic kits for early diagnosis and control the spread of coronavirus. Further, the growing awareness for early detection using specific diagnostic tests, growth in funding for research on infectious disease diagnostics, and shift in focus from centralized laboratories to decentralized point-of-care testing services are expected to propel the growth of the global infectious disease diagnostics market. However, unfavorable and inadequate reimbursement scenario is expected to hamper the growth of the infectious disease diagnostics market.

                                                  Click Here: To Get Your Free Sample Report Now

Impact of COVID-19 on Infectious Disease Diagnostics Market

The rising burden of infectious diseases and hospital acquired infections across the globe has increased the demand for infectious disease diagnostics products. Recent outbreak of the coronavirus disease (COVID-19) which has emerged since November 2019 in Wuhan, China has created destruction in several countries across the world. According to the WHO, as of 28th April 2020, there  were 3,073,603 confirmed cases, 2,11,768 confirmed deaths which has increased to 4,962,707 confirmed cases and 3,26,459 deaths worldwide as of 22nd May 2020. In this global pandemic, although many dedicated healthcare professionals work tirelessly on the frontlines to fight against this crisis, it’s equally important to minimize the spread of disease by early diagnosis. Since its outbreak in November 2019, the disease has spread to many countries around the globe with the World Health Organization declaring it a public health emergency.

Testing is one of the greatest tools in understanding and managing the coronavirus pandemic. In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices to facilitate testing outside of laboratory settings. These simple test kits are based either on detection of proteins from the COVID-19 virus in respiratory samples (e.g. sputum, throat swab) or detection, in blood or serum, of human antibodies generated in response to infection. Organizations around the world, including the Forum and its partners, are coming together and innovating to minimize the impact on public health and to limit disruptions to economies and supply chains. Some of the key initiatives undertaken by the manufacturers and organizations are as follows:

  • European governments have pledged over €7 billion in initial funding, as a part of a global effort to respond to the COVID-19 pandemic.
  • Partner of the World Economic Forum, Novo Nordisk Foundation, has taken an innovative approach since the beginning of the coronavirus pandemic to invest millions into research and development that will prepare Denmark for future viral epidemics. The Novo Nordisk Foundation has awarded a grant to TestCenter Danmark to carry out up to 3 million tests.
  • Global technology leader, Cisco Systems, is committing $225 million to help fight the COVID-19 pandemic.
  • Infosys, Strategic Partner of the Forum, has dedicated $13.6 million (INR 100 crore) in funding for hospital capacity treatment, ventilators, testing kits, and protective gear for frontline health workers to mitigate the impacts of COVID-19 across India.
  • Mylab Discovery Solutions (India), molecular diagnostics company, received commercial licence from the Central Drugs Standard Control Organisation (CDSCO) for its PathoDetect COVID-19 Qualitative PCR kit. The government is sourcing the Covid-19 kits from Germany to facilitate tests for diagnosing people infected with coronavirus across India. The recent validation to Mylab and German’s Altona diagnostics helps towards ramping up Covid-19 testing capacity and reducing the supply shortage of kits.
  • European Institute of Innovation & Technology (EIT) Health has announced funds of almost $7.69 million (7 million euros) in the fight against COVID-19, which will be dedicated to 15 health innovation projects across Europe. The projects will focus on immediate and impactful solutions for better tools in navigating the pandemic. e. the diagnostic testing.
  • Similarly, some of the key players operating in this market such as Abbott Laboratories (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Thermo Fisher Scientific Inc. (U.S.), Accurate Diagnostic Labs (U.S.), and Mylab Discovery Solutions (India) have also developed various diagnostic kits for early detection of COVID-19 in March & April 2020

Shift in focus from centralized laboratories to decentralized point-of-care services to propel the growth of the infectious disease diagnostics market

Molecular diagnostics has been done in centralized laboratories since many years, however, its few drawbacks like delay in results, high cost of tests, less accuracy, and late disease diagnosis have led to continuous shift in decentralizing clinical laboratory testing for infectious disease diagnosis.  Point-of-care (POC) testing is majorly performed for the diagnosis purpose at or near the site where a patient initially encounters the health care system. POC tests have the potential to improve the patient management of infectious diseases. POC tests for various infectious diseases such as Chlamydia, gonorrhea, and influenza, among others, helps in providing early diagnosis and treatment. POC testing in the decentralized set up help the patient and the physicians to monitor the infectious diseases and improve the clinical workflow. In addition, improvement in the information technology contributed significantly in the process of decentralization of clinical laboratory testing.

Thus, the shift towards point of care testing is expected to accelerate the growth of the global infectious disease diagnostics market.

Key Findings in the Global Infectious Disease Diagnostics Market Study:

Immunodiagnostics segment to dominate the infectious disease diagnostics market in 2020

Based on technology, the immunodiagnostics segment is estimated to dominate the overall infectious disease diagnostics market in 2020. The dominance of this segment is mainly attributed to factors such as the Increasing use of immunoassays in infectious disease testing, development of novel tests, rising trend of automation, increasing awareness about health and fitness, and reduced complications associated with the instruments.

Based on products & solution, consumables segment to grow at the fastest CAGR during the forecast period

Based on products and services, the consumables segment is estimated to grow with the fastest CAGR during the forecast period, which is mainly attributed to the factors such as increasing prevalence of infectious diseases, rising awareness among the population to identify the diseases, and increasing use of kits and reagents to identify the organism causing various diseases in lesser time and cost. Further, the outbreak of coronavirus (COVID-19) disease since November 2019 is further expected to accelerate the growth of this segment owing to the national emergency declared and requirement of various kits and assays for early disease detection.

Hepatitis diseases to hold the largest share of the infectious disease diagnostics market in 2020

Based on diseases type, the hepatitis diseases segment is estimated to hold the largest share of the overall infectious disease diagnostics market in 2020. Increasing number of blood transfusions and donations, increasing prevalence of hepatitis B & C infections, rising susceptibility of the geriatric population, growing awareness among the population, and benefits offered by point of care instruments & kits are expected to propel the growth of this segment.

Asia Pacific: The fastest-growing market

At regional level, infectious disease diagnostics market is expected to be dominated by North America in 2020, while, Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of Asia Pacific infectious disease diagnostics market are rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, need to manage growing burden of infectious diseases, and government efforts to improve accessibility of diagnostic services to enhance the prevention by developing products or platforms required for the diagnosis of infectious diseases.

Key Players

The report includes competitive landscape based on extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the past 5 years (2016-2020). The key players profiled in the global infectious disease diagnosis market are Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience Inc. (U.S.), and Quidel Corporation (U.S.).

Scope of the Report:

Infectious Disease Diagnostics Market by Product & Solution

  • Consumables
  • Instruments
  • Software & Services

Infectious Disease Diagnostics Market by Technology

  • Immunodiagnostics
  • Clinical Microbiology
  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification Technology
  • DNA Sequencing and Next-Generation Sequencing (NGS)
  • DNA Microarray Technology
  • Other technologies
    (Other Technologies comprises of microscopy, hybridization, and loop-mediated isothermal amplification)

Infectious Disease Diagnostics Market by Disease Type

  • Hepatitis
  • Human Immunodeficiency Virus (HIV)
  • Hospital-Acquired Infections (HAIS)
  • Human Papillomavirus (HPV)
  • Tuberculosis (TB)
  • Influenza
  • Other Diseases
    (Other diseases comprise of measles, smallpox, mumps, typhoid fever, malaria, meningitis, Ebola virus disease, Lyme disease, coronavirus disease, and whooping cough)

Infectious Disease Diagnostics Market by End User

  • Hospital/Clinical Laboratories
  • Reference Laboratories
  • Academics/Research Institutes
  • Other End Users
    (Other end-users comprise of physician offices, nursing facilities, and home healthcare agencies)

Infectious Disease Diagnostics Market by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report-

The global infectious disease diagnosis market is projected to reach $23.17 billion by 2027, at a CAGR of 7.4% during the forecast period of 2020-2027
Based on technology, the polymerase chain reaction (PCR) segment is expected to register the highest growth during the forecast period. PCR is a diagnostic test designed to confirm clinical disease, infection, or diagnose the cause of death in humans. This technique helps to detect the pathogen itself by amplifying very small traces of DNA and RNA of the pathogens, which are then detected in the assay. Continuous technological advancements in PCR technologies, its ability to detect infections in the latent phase, and less amount of template material requirement for the overall assay are the factors driving the growth of this segment.
The reference laboratories segment is estimated to dominate the infectious disease diagnosis market in 2020 and is projected to register the fastest CAGR during the forecast period, mainly due to large number of samples received by reference laboratories for testing, and well-equipped and high throughput facilities to ensure quick turnaround of tests.
Rising prevalence of acute & chronic diseases; outbreaks of infectious diseases, such as COVID-19 and Ebola; growing awareness about early disease diagnosis; increasing number of hospitals and diagnostic laboratories; rising funds for research activities on infectious disease diagnostics; and shift in focus from centralized laboratories to decentralized point-of-care testing services are some of the major factors driving the growth of the market. In addition, the growing awareness about personalized medicine, advances in genomics and proteomics, current outbreak of COVID-19 pandemic, and growth opportunities in emerging markets provide significant growth opportunities for vendors across the globe.
The global infectious disease diagnostics market is fragmented in nature and the key players, namely, Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland) are majorly driving the innovation trends in the market with their strategic developments.
Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience Inc. (U.S.), and Quidel Corporation (U.S.) are some of the prominent players operating in the market.
The emerging economies like China, India, Brazil, and Mexico based in Asia and Latin America are projected to offer significant growth opportunities for the vendors in this market with rising geriatric population, rapid rise in the prevalence of infectious diseases, growth in per capita income, increasing investments in the healthcare sector, growing number of hospitals and diagnostic laboratories, and sudden outbreak of COVID-19.
This website is secure and we do not share your personal information with any third party. Privacy Policy
Tags: Healthcare In Vitro Diagnostics Medical Technologies
Download Free Sample